See more : Summit Financial Group, Inc. (SMMF) Income Statement Analysis – Financial Results
Complete financial analysis of NuGen Medical Devices Inc. (NGMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NuGen Medical Devices Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Great Panther Mining Limited (0R0D.L) Income Statement Analysis – Financial Results
- Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) Income Statement Analysis – Financial Results
- Wockhardt Limited (WOCKPHARMA.NS) Income Statement Analysis – Financial Results
- WW Holding Inc. (8442.TW) Income Statement Analysis – Financial Results
- Japan Gold Corp. (JGLDF) Income Statement Analysis – Financial Results
NuGen Medical Devices Inc. (NGMDF)
About NuGen Medical Devices Inc.
NuGen Medical Devices Inc., a specialty medical device company, focuses on developing and commercializing novel drug delivery technologies. It offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including anaphylaxis, diabetes, severe migraine, erectile dysfunction, chronic anemia, neutropenia, autoimmune rheumatoid arthritis, growth and fertility hormone, and psoriasis, as well as DNA and conventional/pediatric vaccines. The company was formerly known as BuzBuz Capital Corp. NuGen Medical Devices Inc. is based in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 331.40K | 152.36K | 137.65K | 47.30K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 166.56K | 705.59K | 45.42K | 12.91K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 164.84K | -553.23K | 92.22K | 34.39K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 49.74% | -363.11% | 67.00% | 72.70% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.52M | 4.24M | 1.72M | 0.00 | 995.65K | 603.33K | 415.77K |
| Selling & Marketing | 0.00 | 0.00 | 6.05M | 2.65M | 478.44K | 582.57K | 98.78K |
| SG&A | 7.52M | 4.24M | 7.76M | 2.65M | 132.14K | 1.66M | 608.03K |
| Other Expenses | 690.84K | 57.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.21M | 4.24M | 7.76M | 2.65M | 132.14K | 1.65M | 610.57K |
| Cost & Expenses | 8.38M | 4.95M | 7.81M | 2.66M | 132.14K | 1.65M | 610.57K |
| Interest Income | 0.00 | 150.91K | 20.00K | 22.85K | 0.00 | 136.87K | 104.42K |
| Interest Expense | 1.24M | 1.01M | 1.22M | 672.19K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 690.84K | 652.40K | 626.94K | 387.78K | 1.20K | 1.29K | 1.76K |
| EBITDA | -7.40M | -4.14M | -5.17M | -2.22M | -132.14K | -1.66M | -608.03K |
| EBITDA Ratio | -2,233.32% | -2,718.36% | -4,979.77% | -5,135.51% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.05M | -4.79M | -7.67M | -2.61M | -132.14K | -1.66M | -609.79K |
| Operating Income Ratio | -2,428.48% | -3,146.56% | -5,573.13% | -5,521.05% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.28M | -780.71K | -1.31M | -1.05M | -24.20K | -129.70K | -105.20K |
| Income Before Tax | -9.33M | -5.57M | -7.10M | -3.66M | -156.34K | -1.79M | -714.98K |
| Income Before Tax Ratio | -2,814.83% | -3,658.98% | -5,161.08% | -7,734.93% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 33.80K | 3.18K | 2.96K | 12.17K | -1.20K | 0.00 | 0.00 |
| Net Income | -9.36M | -5.58M | -7.11M | -3.67M | -156.34K | -1.79M | -714.98K |
| Net Income Ratio | -2,825.02% | -3,661.07% | -5,163.23% | -7,760.66% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.06 | -0.10 | -0.14 | -0.03 | -0.09 | -0.07 |
| EPS Diluted | -0.06 | -0.06 | -0.10 | -0.14 | -0.03 | -0.09 | -0.07 |
| Weighted Avg Shares Out | 167.66M | 90.10M | 68.67M | 27.05M | 4.75M | 19.65M | 9.70M |
| Weighted Avg Shares Out (Dil) | 167.66M | 90.10M | 68.67M | 27.05M | 4.75M | 19.65M | 9.70M |
NuGen Announces Canada-Wide Launch of InsuJet
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across Canada Toronto, Ontario--(Newsfile Corp. - November 22, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased...
NuGen Announces Results of Special Meeting and Appointment of New Directors
Toronto, Ontario--(Newsfile Corp. - November 14, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that its shareholders have approved Sol-Millennium Medical HK...
NuGen Announces Strategic Partnership with EziAutoJector Limited
5,000 InsuJet devices to be delivered to the UK Toronto, Ontario--(Newsfile Corp. - October 25, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to...
NuGen Announces Closing of Private Placement of $10 million Secured Convertible Debentures
Toronto, Ontario--(Newsfile Corp. - September 20, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that, further to its press release dated August...
NuGen Announces Release of Financial Results for Q2 2024 & Update on Proposed Private Placement
Toronto, Ontario--(Newsfile Corp. - August 29, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices for the subcutaneous administration of therapeutics, announces the release of Q2 2024 Financial Results and is...
NuGen Announces Voting Results of Annual and Special Meeting
Toronto, Ontario--(Newsfile Corp. - August 21, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce voting results from the annual and special meeting...
NuGen Announces Revised Terms of Proposed Private Placement of up to $10 Million Secured Convertible Debentures
Toronto, Ontario--(Newsfile Corp. - August 15, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, announces that price protection has expired for its proposed non-brokered private placement...
NuGen Receives Order for Repeat Demand in Mexico
Toronto, Ontario--(Newsfile Corp. - July 19, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that Science Link, the exclusive distributor of the...
NuGen Announces Proposed Private Placement of up to $10 million Secured Convertible Debentures
Toronto, Ontario--(Newsfile Corp. - July 10, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce its intention to complete a non-brokered private placement...
NuGen Develops Pharmacist Training Packages for the Canadian Retail Pharmacy Market
Toronto, Ontario--(Newsfile Corp. - July 9, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that it has formed a three-way partnership with...
Source: https://incomestatements.info
Category: Stock Reports